Breaks Categories: News

MondayNov 25, 2024 11:04 am

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Presents Progress in Pivotal Study of Berubicin for Glioblastoma Treatment

CNS Pharmaceuticals (NASDAQ: CNSP) announced updated results from its ongoing pivotal trial evaluating Berubicin, a novel anthracycline crossing the blood-brain barrier, against Lomustine in recurrent glioblastoma multiforme (“GBM”). Presented at the 29th Annual Meeting of the Society for Neuro-Oncology, the data show balanced patient demographics and safety profiles between the study arms, with Berubicin showing comparable adverse event rates and promising potential to improve overall survival (“OS”), the trial's primary endpoint. With enrollment completed at 252 patients, CNS expects to report primary analysis data in early 2025. Berubicin holds FDA Fast Track and Orphan Drug Designations, underscoring its significance in…

Continue Reading

MondayNov 25, 2024 10:09 am

BioMedNewsBreaks — HealthLynked Corp. Completes $3 Million Cash Consideration from ACO Health Partners Sale

HealthLynked (OTCQB: HLYK) announced the receipt of $500,000 as part of its contractual share of shared savings generated by ACO Health Partners (AHP) during the 2023 performance period. This marks the final payment under the terms of the January 2023 sale of AHP, bringing the total gross proceeds to $3 million, including $750,000 from the initial sale and $1.75 million in participation-based payments. CEO Dr. Michael Dent highlighted the strategic value of the sale, enabling HealthLynked to focus on advancing its core healthcare technology and patient engagement solutions. To view the full press release, visit https://ibn.fm/dyOwj About HealthLynked Corp. HealthLynked…

Continue Reading

MondayNov 25, 2024 8:25 am

BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast to Share Clinical and Strategic Updates

Annovis Bio (NYSE: ANVS), a clinical-stage company developing therapies for neurodegenerative diseases, will host a live investor webcast on Dec. 11, 2024, at 4:30 PM EST. Led by Founder and CEO Dr. Maria Maccecchini, the event will highlight updates on Phase 3 studies for Parkinson’s and Alzheimer’s diseases, regulatory milestones, financial strategies, and plans for advancing neurodegenerative therapies in 2025. To view the full press release, visit https://ibn.fm/7SWXi About Annovis Bio Inc. Annovis Bio, headquartered in Malvern, Pennsylvania, is committed to addressing neurodegeneration in diseases such as Alzheimer’s and Parkinson’s. The company is developing innovative therapies that target multiple neurotoxic…

Continue Reading

FridayNov 22, 2024 12:47 pm

BioMedNewsBreaks — IBN, BioMedWire Continue Collaboration to Amplify Reach of Dynamic Global Events’ 2025 Lineup

IBN, a leading communications organization with an extensive portfolio of over 60 brands, today announced its fifth consecutive year partnering with Dynamic Global Events (“DGE”) as an official media sponsor for 2025. BioMedWire (“BMW”), IBN’s digital platform dedicated to emerging life sciences opportunities, will also serve as a media partner, expanding DGE's event reach and visibility throughout the year. DGE serves the pharmaceutical and life sciences sectors with educational B2B events that drive industry networking, partnership opportunities and business development. “We are thrilled to extend our collaboration with IBN and BioMedWire for another year,” said DGE’s Head of Marketing, Elizabeth…

Continue Reading

FridayNov 22, 2024 8:05 am

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports Nine-Month Financial Results and Business Update

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing innovative biological products targeting inflammation and immunology (“I&I”) and offering contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservices division, released its financial results for the nine months ending Sept. 30, 2024. The announcement highlights the company’s progress in advancing its I&I-focused pipeline and the expansion of its CDMO operations, showcasing its commitment to delivering high-quality biologics and fostering strategic partnerships. This update reflects Scinai’s efforts to strengthen its position in the biopharmaceutical and CDMO markets, aligning with its broader vision of growth and innovation. To view the…

Continue Reading

TuesdayNov 19, 2024 11:10 am

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Presents Positive Data for Groundbreaking Technology at AHA Conference

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights wherever the patient is, today announced the results from two studies evaluating its groundbreaking vector-based technology. According to the announcement, the data add to the body of evidence for HeartBeam’s key clinical indications, specifically arrhythmia and heart attack (myocardial infarction) detection, and showcase the technology’s pivotal role in advancing patient care. The studies were presented during the American Heart Association’s annual Scientific Sessions in Chicago, Nov. 16-18, 2024. “The data presentations at AHA are a testament to HeartBeam’s dedication to building a robust…

Continue Reading

TuesdayNov 19, 2024 9:30 am

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Raises $7.5 Million Through Public Stock Offering

Calidi Biotherapeutics (NYSE American: CLDI) announced the successful closing of a public offering of 4,437,869 shares of common stock at $1.69 per share, raising approximately $7.5 million in gross proceeds. Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent for the offering, which was conducted under an effective registration statement on Form S-3 filed with the SEC. The final prospectus is available on the SEC’s website or through Ladenburg Thalmann. The offering complies with all relevant securities laws and regulations. To view the full press release, visit: https://ibn.fm/5LDBg About Calidi Biotherapeutics Calidi Biotherapeutics specializes in proprietary technology that…

Continue Reading

MondayNov 18, 2024 11:51 am

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present Berubicin Trial Update at Society for Neuro-Oncology Annual Meeting

CNS Pharmaceuticals (NASDAQ: CNSP) announced that its abstract on the pivotal trial of Berubicin, a novel treatment for glioblastoma multiforme (“GBM”), has been selected for poster presentation at the 29th Annual Meeting of the Society for Neuro-Oncology. The presentation, led by Chief Medical Officer Dr. Sandra Silberman, will provide updates on the randomized, controlled CNS-201 trial comparing Berubicin to Lomustine after first-line GBM therapy. The session will take place on Nov. 22, 2024, at the George R. Brown Convention Center in Houston, TX, during the Poster and Networking Session. To view the full press release, visit https://ibn.fm/NjZCs About CNS Pharmaceuticals…

Continue Reading

MondayNov 18, 2024 11:26 am

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Showcases RTNova Virotherapy Breakthrough for Metastatic Cancer Treatment

Calidi Biotherapeutics (NYSE American: CLDI) presented data at the International Oncolytic Virotherapy Conference and the Society for Immunotherapy of Cancer Annual Meeting highlighting its RTNova™ systemic virotherapy technology. This innovative platform leverages a tumor-selective vaccinia virus enhanced with extracellular enveloped viruses (“EEVs”) to overcome challenges like immune clearance and limited targeting in systemic virotherapy. RTNova demonstrated potential to target and kill metastatic tumor sites across multiple oncology indications, including metastatic lung cancer, while transforming tumor microenvironments and delivering therapeutic payloads. These findings position RTNova as a groundbreaking approach for addressing advanced metastatic diseases, supporting Calidi’s mission to develop multi-modal, off-the-shelf…

Continue Reading

MondayNov 18, 2024 8:45 am

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL) Expands OPKO Product Promotion at Asia’s Largest Health Expo in China

NextPlat (NASDAQ: NXPL, NXPLW) announced its participation in the 2024 China International Natural Health & Nutrition Expo (“NHNE”) in Wuhan, showcasing OPKO Health Europe products, including new veterinary and animal care offerings. Supported by its in-country marketing partner, NextPlat has seen increasing demand for OPKO products in China, fueled by online and offline promotional campaigns. The company is leveraging NHNE to connect with thousands of potential retail and distribution partners while launching OPKO storefronts on major Chinese platforms like WeChat and JD.com. NextPlat aims to secure broader physical distribution in major retail chains by 2025, advancing its strategy to capitalize…

Continue Reading